Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Chronic Refractory Cough treatment market Snapshot (2023 to 2033)

The global chronic refractory cough treatment market is expected to reach a valuation of US$ 9.2 billion in 2023 and is projected to reach USD 17.1 billion by 2033, trailing a CAGR of 6.39%.

The growing prevalence of refractory chronic cough globally drives the refractory chronic cough therapeutics market. Increased global healthcare spending and disease awareness would increase the market's size, allowing pharmaceutical companies to expand their market share. The medicines in development are centered on cutting-edge methods to treat or ameliorate the illness state.

Report Attribute Details
Expected Market Value (2023) US$ 9.2 billion
Anticipated Forecast Value (2033) US$ 17.1 billion
Projected Growth Rate (2023 to 2033) CAGR 6.39%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Chronic Refractory Cough Management Demand Analysis vs. Forecast 2023 to 2033

The chronic refractory cough treatment market was worth US$ 7 billion in 2018 while growing at a CAGR of 5.62%. In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.

Since chronic cough causes increased body pain, companies in the Chronic refractory cough treatment market are increasing the availability of gabapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that; gabapentin is well-tolerated for the treatment of refractory chronic cough. Thus, leading to market expansion.

Considering these factors, the market for Chronic refractory cough treatment is projected to reach US$ 17.1 billion by end of the forecast period, while exhibiting a CAGR of 6.39%.

Which are Some Prominent Drivers of the Chronic Refractory Cough Treatment Market?

Launch of pipeline therapies augmenting the market expansion

The launch of pipeline therapies in late and mid-stage developments, including Orvepitant Maleate, BLU-5937, Gefapixant, BAY1817080, and S-600918, is anticipated to expand the growth quadrant of the Chronic Refractory Cough market size in the coming years. Gefapixant (Merck) is currently in the Phase III stage of development, followed by Orvepitant Maleate (Nerre Therapeutics) which will support market growth.

Also, the use of various off-label therapies and over-the-counter drugs like Neuro-modulating agents (Opioids, Baclofen, Gabapentin, Pregabalin, and Amitriptyline), Proton Pump inhibitors, Inhaled corticosteroids (ICS), and others along with non-pharmacological treatments like speech therapy will fuel product demand. Orvepitant Maleate has demonstrated no safety concerns in the treated population with excellent tolerability. If approved, the drug has the potential to capture a major market share. Thus, leading to market expansion.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Lack of approved therapies to restrain the growth

A severe dearth of approved therapies in the chronic refractory cough treatment market may restrain its success trajectory. There is a lack of availability of specific biomarkers that can help in the accurate and timely diagnosis of Chronic Refractory Cough. These factors will hamper market expansion.

Region-Wise Insights

What is the growth outlook in North America?

North America leading the market with a significant market share

The North American chronic refractory cough treatment market is projected to reach US$ 6.84 billion by 2033 from US$ 3.9 billion in 2023. It is estimated to grow with a CAGR of 5.77% during the forecast period. This region is expected to dominate the market with a 40% market share, owing to the presence of major market players.

The USA leads the market in this region with approximately 71% market share. Several collaborative efforts were undertaken by major companies to enhance their Research and Development capabilities and ensure high medical standards are expected to impel the demand across this region. Moreover, the majority share can also be attributed to the high disease burden in this region. Rising cases of cough and the rising pediatric population are the key factors that are fuelling the market in this region.

What are the growth prospects in South Asia?

South Asian market to witness the fastest growth

South Asia region is expected to witness the fastest growth of 6.2% over the forecast period. The market in this region is estimated to be worth US$ 4.78 billion, accounting for 28% market share by end of the forecast period.

Strategic partnerships between pharmaceutical companies and government organizations are on a rise in the region, particularly to develop generic drugs and spread awareness amongst healthcare professionals. Growing awareness levels and the rising focus of healthcare providers on the eradication of coughing ailments are expected to boost growth within this region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

By Distribution Channel, which segment will possess the Highest Share?

Retail Pharmacies are dominating the market and driving growth

The retail pharmacy segment is expected to dominate the market with a 55% market share. Growth is attributable to the easy availability and accessibility of these pharmacies. For instance, MedPlus has around 1650 outlets out of which 1,350 are self-owned and the rest are taken as a franchisee. Retailers provide discounts on bulk purchases, offer quick delivery, and always have sufficient product stock, owing to which consumers opt for these distribution channels, thus, driving the segment’s growth.

By Distribution Channel, which segment will experience the Fastest Expansion?

Online Pharmacies to experience Maximum Sales of Chronic Refractory Cough Treatment Drugs

Online pharmacies are estimated to be the fastest-growing segment with a CAGR of 8% during the forecast period. The convenience of delivering medicines to the doorstep is the major advantage of online pharmacies.

The discounted price that online pharmacies offer is also a factor that drives the growth of the Chronic refractory cough treatment market. As per an estimate, there are between 30,000 and 50,000 online pharmacies operating in the United States alone, making online pharmacies a leading segment in this region.

By Drug Class, which segment exhibits significant market share?

Antibiotics to take the lead and drive market growth

This segment is projected to achieve a 45.7% market share by end of the forecast period. The growing usage of antibiotic drugs for the treatment of chronic refractory cough and ongoing research on the development of effective antibiotic therapies are leading to the growth of the antibiotic drug class segment in the global chronic refractory cough treatment market.

Start-ups in Chronic Refractory Cough Treatment Market

  • Founded in 2009, Afferent Pharmaceutical is a US-based, clinical-stage biopharmaceutical company that develops small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory, and urological conditions. Its products include AF-219 which is used for patients with osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis/bladder pain syndrome; and AF-220, a second-generation P2X3 antagonist. It received funding of USD 88.1 million from Fidelity Investments, Jennison Associates, and 4 more
  • Founded in 2017, Nocion Therapeutics is a Waltham, US-based start-up that is involved in developing therapies for treating cough, itch, pain, and inflammation diseases. It has developed a proprietary platform through which they are developing small molecules called notions, which target activated sensory neurons. It enters inflamed nociceptors through large-pore channels. It received funding of USD 42 million from Canaan Partners, F-Prime Capital, and 2 others.

Market Competition

The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are: Bayer AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Mylan N.V., GlaxoSmithKline, Hikma Pharmaceuticals Plc, AstraZeneca, Bausch Health, Novartis AG, Cipla Inc, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd, Alitair Pharmaceuticals, NeRRe Therapeutics, Amneal Pharmaceuticals, Inc

Some recent developments in this industry are:

  • On September 6, 2021, Bayer AG announced the results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of its investigational orally administered, potent, and selective P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough (RCC).
  • The primary efficacy outcome was met showing a statistically significant reduction in the 24-hour cough count (average hourly cough frequency based on 24-hour sound recordings) of up to 27% for eliapixant 75 mg twice daily over placebo after 12 weeks of treatment.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 9.2 billion
Market Value in 2033 US$ 17.1 billion
Growth Rate CAGR of 6.39% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • India
  • China
  • Japan
  • Malaysia
  • Singapore
  • Thailand
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Mylan N.V.
  • GSK Plc.
  • Hikma Pharmaceuticals Plc
  • AstraZeneca Plc.
  • Bausch Health
  • Novartis AG
  • Cipla Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Alitair Pharmaceuticals
  • NeRRe Therapeutics
  • Amneal Pharmaceuticals Inc.
Customization Available Upon Request

Key Segments Profiled in the Chronic Refractory Cough Treatment Industry Survey

By Drug Class:

  • Antibiotics
  • Decongestants
  • Corticosteroids
  • Antihistamines
  • Acid Blockers
  • Others

By Route of administration:

  • Oral
  • Nasal
  • Parenteral
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the anticipated growth of the chronic refractory cough treatment market until 2033?

FMI projects the global Chronic Refractory Cough treatment market to expand at a 6.39 % value CAGR by 2033.

What is the estimated market value of the chronic refractory cough treatment market expected in 2033?

The global chronic refractory cough treatment market is expected to garner a market value of US$ 17.1 billion by 2033.

Which region is forecast to be the most lucrative for chronic refractory cough treatment market growth?

FMI has projected North America to be one of the most profitable regions for the chronic refractory cough treatment market.

Which region is expected to grow fastest during the forecast period?

South Asia region is expected to grow fastest during the forecast period, expanding at a 6.2% CAGR

What is the Market Value in 2023?

The market in 2023 is valued at US$ 9.2 billion.

What is the Growth Outlook for the Market?

The market is anticipated to experience a 6.39% CAGR from 2023 to 2033.

How did the Market Perform Historically?

From 2018 to 2022, the market expanded at a 5.62% CAGR.

What is the Estimated Market Value for 2033?

By 2033, the market is estimated to reach US$ 17.1 billion.

What is South Asia’s Market CAGR over the Forecast period?

South Asia is likely to expand at a CAGR of 6.2% over the forecast period. 

Table of Content

1. Executive Summary | Chronic Refractory Cough Treatment Market

        1.1. Global Market Outlook

        1.2. Demand-side Trends

        1.3. Supply-side Trends

        1.4. Technology Roadmap Analysis

        1.5. Analysis and Recommendations

2. Market Overview

        2.1. Market Coverage / Taxonomy

        2.2. Market Definition / Scope / Limitations

3. Market Background

        3.1. Market Dynamics

            3.1.1. Drivers

            3.1.2. Restraints

            3.1.3. Opportunity

            3.1.4. Trends

        3.2. Scenario Forecast

            3.2.1. Demand in Optimistic Scenario

            3.2.2. Demand in Likely Scenario

            3.2.3. Demand in Conservative Scenario

        3.3. Opportunity Map Analysis

        3.4. Investment Feasibility Matrix

        3.5. PESTLE and Porter’s Analysis

        3.6. Regulatory Landscape

            3.6.1. By Key Regions

            3.6.2. By Key Countries

        3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

        4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

        4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

            4.2.1. Y-o-Y Growth Trend Analysis

            4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

        5.1. Introduction / Key Findings

        5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

        5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

            5.3.1. Antibiotics

            5.3.2. Decongestants

            5.3.3. Corticosteroids

            5.3.4. Antihistamines

            5.3.5. Acid Blockers

            5.3.6. Others

        5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

        5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

        6.1. Introduction / Key Findings

        6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

        6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

            6.3.1. Oral

            6.3.2. Nasal

            6.3.3. Parenteral

            6.3.4. Others

        6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

        6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 

        7.1. Introduction / Key Findings

        7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

        7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

        7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

        7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

        8.1. Introduction

        8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

        8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

            8.3.1. North America

            8.3.2. Latin America

            8.3.3. Europe

            8.3.4. South Asia

            8.3.5. East Asia

            8.3.6. Oceania

            8.3.7. Middle East & Africa (MEA)

        8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            9.2.1. By Country

                9.2.1.1. USA

                9.2.1.2. Canada

            9.2.2. By Drug Class

            9.2.3. By Route of Administration

            9.2.4. By Distribution Channel

        9.3. Market Attractiveness Analysis

            9.3.1. By Country

            9.3.2. By Drug Class

            9.3.3. By Route of Administration

            9.3.4. By Distribution Channel

        9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            10.2.1. By Country

                10.2.1.1. Brazil

                10.2.1.2. Mexico

                10.2.1.3. Rest of Latin America

            10.2.2. By Drug Class

            10.2.3. By Route of Administration

            10.2.4. By Distribution Channel

        10.3. Market Attractiveness Analysis

            10.3.1. By Country

            10.3.2. By Drug Class

            10.3.3. By Route of Administration

            10.3.4. By Distribution Channel

        10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            11.2.1. By Country

                11.2.1.1. Germany

                11.2.1.2. UK

                11.2.1.3. France

                11.2.1.4. Spain

                11.2.1.5. Italy

                11.2.1.6. Rest of Europe

            11.2.2. By Drug Class

            11.2.3. By Route of Administration

            11.2.4. By Distribution Channel

        11.3. Market Attractiveness Analysis

            11.3.1. By Country

            11.3.2. By Drug Class

            11.3.3. By Route of Administration

            11.3.4. By Distribution Channel

        11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            12.2.1. By Country

                12.2.1.1. India

                12.2.1.2. Malaysia

                12.2.1.3. Singapore

                12.2.1.4. Thailand

                12.2.1.5. Rest of South Asia

            12.2.2. By Drug Class

            12.2.3. By Route of Administration

            12.2.4. By Distribution Channel

        12.3. Market Attractiveness Analysis

            12.3.1. By Country

            12.3.2. By Drug Class

            12.3.3. By Route of Administration

            12.3.4. By Distribution Channel

        12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            13.2.1. By Country

                13.2.1.1. China

                13.2.1.2. Japan

                13.2.1.3. South Korea

            13.2.2. By Drug Class

            13.2.3. By Route of Administration

            13.2.4. By Distribution Channel

        13.3. Market Attractiveness Analysis

            13.3.1. By Country

            13.3.2. By Drug Class

            13.3.3. By Route of Administration

            13.3.4. By Distribution Channel

        13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            14.2.1. By Country

                14.2.1.1. Australia

                14.2.1.2. New Zealand

            14.2.2. By Drug Class

            14.2.3. By Route of Administration

            14.2.4. By Distribution Channel

        14.3. Market Attractiveness Analysis

            14.3.1. By Country

            14.3.2. By Drug Class

            14.3.3. By Route of Administration

            14.3.4. By Distribution Channel

        14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            15.2.1. By Country

                15.2.1.1. GCC Countries

                15.2.1.2. South Africa

                15.2.1.3. Israel

                15.2.1.4. Rest of MEA

            15.2.2. By Drug Class

            15.2.3. By Route of Administration

            15.2.4. By Distribution Channel

        15.3. Market Attractiveness Analysis

            15.3.1. By Country

            15.3.2. By Drug Class

            15.3.3. By Route of Administration

            15.3.4. By Distribution Channel

        15.4. Key Takeaways

16. Key Countries Market Analysis

        16.1. US

            16.1.1. Pricing Analysis

            16.1.2. Market Share Analysis, 2022

                16.1.2.1. By Drug Class

                16.1.2.2. By Route of Administration

                16.1.2.3. By Distribution Channel

        16.2. Canada

            16.2.1. Pricing Analysis

            16.2.2. Market Share Analysis, 2022

                16.2.2.1. By Drug Class

                16.2.2.2. By Route of Administration

                16.2.2.3. By Distribution Channel

        16.3. Brazil

            16.3.1. Pricing Analysis

            16.3.2. Market Share Analysis, 2022

                16.3.2.1. By Drug Class

                16.3.2.2. By Route of Administration

                16.3.2.3. By Distribution Channel

        16.4. Mexico

            16.4.1. Pricing Analysis

            16.4.2. Market Share Analysis, 2022

                16.4.2.1. By Drug Class

                16.4.2.2. By Route of Administration

                16.4.2.3. By Distribution Channel

        16.5. Germany

            16.5.1. Pricing Analysis

            16.5.2. Market Share Analysis, 2022

                16.5.2.1. By Drug Class

                16.5.2.2. By Route of Administration

                16.5.2.3. By Distribution Channel

        16.6. UK

            16.6.1. Pricing Analysis

            16.6.2. Market Share Analysis, 2022

                16.6.2.1. By Drug Class

                16.6.2.2. By Route of Administration

                16.6.2.3. By Distribution Channel

        16.7. France

            16.7.1. Pricing Analysis

            16.7.2. Market Share Analysis, 2022

                16.7.2.1. By Drug Class

                16.7.2.2. By Route of Administration

                16.7.2.3. By Distribution Channel

        16.8. Spain

            16.8.1. Pricing Analysis

            16.8.2. Market Share Analysis, 2022

                16.8.2.1. By Drug Class

                16.8.2.2. By Route of Administration

                16.8.2.3. By Distribution Channel

        16.9. Italy

            16.9.1. Pricing Analysis

            16.9.2. Market Share Analysis, 2022

                16.9.2.1. By Drug Class

                16.9.2.2. By Route of Administration

                16.9.2.3. By Distribution Channel

        16.10. India

            16.10.1. Pricing Analysis

            16.10.2. Market Share Analysis, 2022

                16.10.2.1. By Drug Class

                16.10.2.2. By Route of Administration

                16.10.2.3. By Distribution Channel

        16.11. Malaysia

            16.11.1. Pricing Analysis

            16.11.2. Market Share Analysis, 2022

                16.11.2.1. By Drug Class

                16.11.2.2. By Route of Administration

                16.11.2.3. By Distribution Channel

        16.12. Singapore

            16.12.1. Pricing Analysis

            16.12.2. Market Share Analysis, 2022

                16.12.2.1. By Drug Class

                16.12.2.2. By Route of Administration

                16.12.2.3. By Distribution Channel

        16.13. Thailand

            16.13.1. Pricing Analysis

            16.13.2. Market Share Analysis, 2022

                16.13.2.1. By Drug Class

                16.13.2.2. By Route of Administration

                16.13.2.3. By Distribution Channel

        16.14. China

            16.14.1. Pricing Analysis

            16.14.2. Market Share Analysis, 2022

                16.14.2.1. By Drug Class

                16.14.2.2. By Route of Administration

                16.14.2.3. By Distribution Channel

        16.15. Japan

            16.15.1. Pricing Analysis

            16.15.2. Market Share Analysis, 2022

                16.15.2.1. By Drug Class

                16.15.2.2. By Route of Administration

                16.15.2.3. By Distribution Channel

        16.16. South Korea

            16.16.1. Pricing Analysis

            16.16.2. Market Share Analysis, 2022

                16.16.2.1. By Drug Class

                16.16.2.2. By Route of Administration

                16.16.2.3. By Distribution Channel

        16.17. Australia

            16.17.1. Pricing Analysis

            16.17.2. Market Share Analysis, 2022

                16.17.2.1. By Drug Class

                16.17.2.2. By Route of Administration

                16.17.2.3. By Distribution Channel

        16.18. New Zealand

            16.18.1. Pricing Analysis

            16.18.2. Market Share Analysis, 2022

                16.18.2.1. By Drug Class

                16.18.2.2. By Route of Administration

                16.18.2.3. By Distribution Channel

        16.19. GCC Countries

            16.19.1. Pricing Analysis

            16.19.2. Market Share Analysis, 2022

                16.19.2.1. By Drug Class

                16.19.2.2. By Route of Administration

                16.19.2.3. By Distribution Channel

        16.20. South Africa

            16.20.1. Pricing Analysis

            16.20.2. Market Share Analysis, 2022

                16.20.2.1. By Drug Class

                16.20.2.2. By Route of Administration

                16.20.2.3. By Distribution Channel

        16.21. Israel

            16.21.1. Pricing Analysis

            16.21.2. Market Share Analysis, 2022

                16.21.2.1. By Drug Class

                16.21.2.2. By Route of Administration

                16.21.2.3. By Distribution Channel

17. Market Structure Analysis

        17.1. Competition Dashboard

        17.2. Competition Benchmarking

        17.3. Market Share Analysis of Top Players

            17.3.1. By Regional

            17.3.2. By Drug Class

            17.3.3. By Route of Administration

            17.3.4. By Distribution Channel

18. Competition Analysis

        18.1. Competition Deep Dive

            18.1.1. Bayer AG

                18.1.1.1. Overview

                18.1.1.2. Product Portfolio

                18.1.1.3. Profitability by Market Segments

                18.1.1.4. Sales Footprint

                18.1.1.5. Strategy Overview

                    18.1.1.5.1. Marketing Strategy

            18.1.2. Sun Pharmaceutical Industries Ltd

                18.1.2.1. Overview

                18.1.2.2. Product Portfolio

                18.1.2.3. Profitability by Market Segments

                18.1.2.4. Sales Footprint

                18.1.2.5. Strategy Overview

                    18.1.2.5.1. Marketing Strategy

            18.1.3. Aurobindo Pharma Ltd

                18.1.3.1. Overview

                18.1.3.2. Product Portfolio

                18.1.3.3. Profitability by Market Segments

                18.1.3.4. Sales Footprint

                18.1.3.5. Strategy Overview

                    18.1.3.5.1. Marketing Strategy

            18.1.4. Mylan N.V.

                18.1.4.1. Overview

                18.1.4.2. Product Portfolio

                18.1.4.3. Profitability by Market Segments

                18.1.4.4. Sales Footprint

                18.1.4.5. Strategy Overview

                    18.1.4.5.1. Marketing Strategy

            18.1.5. GlaxoSmithKline

                18.1.5.1. Overview

                18.1.5.2. Product Portfolio

                18.1.5.3. Profitability by Market Segments

                18.1.5.4. Sales Footprint

                18.1.5.5. Strategy Overview

                    18.1.5.5.1. Marketing Strategy

            18.1.6. Hikma Pharmaceuticals Plc

                18.1.6.1. Overview

                18.1.6.2. Product Portfolio

                18.1.6.3. Profitability by Market Segments

                18.1.6.4. Sales Footprint

                18.1.6.5. Strategy Overview

                    18.1.6.5.1. Marketing Strategy

            18.1.7. AstraZeneca

                18.1.7.1. Overview

                18.1.7.2. Product Portfolio

                18.1.7.3. Profitability by Market Segments

                18.1.7.4. Sales Footprint

                18.1.7.5. Strategy Overview

                    18.1.7.5.1. Marketing Strategy

            18.1.8. Bausch Health

                18.1.8.1. Overview

                18.1.8.2. Product Portfolio

                18.1.8.3. Profitability by Market Segments

                18.1.8.4. Sales Footprint

                18.1.8.5. Strategy Overview

                    18.1.8.5.1. Marketing Strategy

            18.1.9. Novartis AG

                18.1.9.1. Overview

                18.1.9.2. Product Portfolio

                18.1.9.3. Profitability by Market Segments

                18.1.9.4. Sales Footprint

                18.1.9.5. Strategy Overview

                    18.1.9.5.1. Marketing Strategy

            18.1.10. Cipla Inc.

                18.1.10.1. Overview

                18.1.10.2. Product Portfolio

                18.1.10.3. Profitability by Market Segments

                18.1.10.4. Sales Footprint

                18.1.10.5. Strategy Overview

                    18.1.10.5.1. Marketing Strategy

            18.1.11. Glenmark Pharmaceuticals Ltd.

                18.1.11.1. Overview

                18.1.11.2. Product Portfolio

                18.1.11.3. Profitability by Market Segments

                18.1.11.4. Sales Footprint

                18.1.11.5. Strategy Overview

                    18.1.11.5.1. Marketing Strategy

            18.1.12. Teva Pharmaceutical Industries Ltd

                18.1.12.1. Overview

                18.1.12.2. Product Portfolio

                18.1.12.3. Profitability by Market Segments

                18.1.12.4. Sales Footprint

                18.1.12.5. Strategy Overview

                    18.1.12.5.1. Marketing Strategy

            18.1.13. Alitair Pharmaceuticals

                18.1.13.1. Overview

                18.1.13.2. Product Portfolio

                18.1.13.3. Profitability by Market Segments

                18.1.13.4. Sales Footprint

                18.1.13.5. Strategy Overview

                    18.1.13.5.1. Marketing Strategy

            18.1.14. NeRRe Therapeutics

                18.1.14.1. Overview

                18.1.14.2. Product Portfolio

                18.1.14.3. Profitability by Market Segments

                18.1.14.4. Sales Footprint

                18.1.14.5. Strategy Overview

                    18.1.14.5.1. Marketing Strategy

            18.1.15. AMillioneal Pharmaceuticals, Inc.

                18.1.15.1. Overview

                18.1.15.2. Product Portfolio

                18.1.15.3. Profitability by Market Segments

                18.1.15.4. Sales Footprint

                18.1.15.5. Strategy Overview

                    18.1.15.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel/, 2023 to 2033

Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033

Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Airway Disease Treatment Market

Published : October 2022

Healthcare

Cold, Cough and Sore Throat Remedies Market

Published : September 2022

Explore Healthcare Insights

View Reports

Chronic Refractory Cough Treatment Market